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Novel therapeutics such as inhibitors of PI3K/Akt/mTOR pathway presents a unique opportunity for the management of diabetic
retinopathy (DR). Second generation mTOR inhibitors have the prospect to be eﬃcacious in managing various stages of disease
progression in DR. During early stages, the mTOR inhibitors suppress HIF-1α, VEGF, leakage, and breakdown of the blood-ret-
inal barrier. These mTOR inhibitors impart a pronounced inhibitory eﬀect on inﬂammation, an early component with diverse
ramiﬁcations inﬂuencing the progression of DR. These inhibitors suppress IKK and NF-κB along with downstream inﬂammatory
cytokines, chemokines, and adhesion molecules. In proliferative DR, mTOR inhibitors suppress several growth factors that play
pivotal rolesintheinduction ofpathological angiogenesis. Lead mTORinhibitorsinclinical trialsforocular indications presentan
attractive treatment option for chronic use in DR with favorable safety proﬁle and sustained ocular pharmacokinetics following
single dose. Thereby, reducing dosing frequency and risk associated with chronic drug administration.
1.Introduction
Blindness as a consequence of diabetic retinopathy from
long-standing or poorly controlled diabetes causes profound
adverse psychological eﬀects to the diabetic patient. Diabetic
retinopathy has a signiﬁcant economic impact on society in
terms of healthcare resources that are required and the po-
tential of loss in the workforce. The number of people at risk
of blindness from diabetic retinopathy in the United States
alone continues to rise, and diabetic retinopathy is the lead-
ing cause of blindness in the industrialized world covering
a wide age range in adults [1]. Diabetic retinopathy aﬀects
75% of all diabetics after 15 years of the disease and up to
97.5% after 15 years of the disease when diagnosis is made
prior to 30 years of age [2]. One in ﬁve patients will
progress to develop proliferative retinopathy after 25 years
of known diabetes [2] Predictions for the prevalence of
diabetic retinopathy in the USA over the next 39 years for
those older than 40 years are 16 million and for those over
65 years are 9.9 million [3]. Moreover, by the year 2050,
those aﬄicted with a sight-threatening stage of proliferative
diabetic retinopathy are projected to be 3.4 million for those
over 40 years of age and 1.9 million for those 65 years of
age or older [3]. Tight control of presumed key risk factors
now appears to be insuﬃcient in minimizing the prevalence
ofsight-threateningproliferativeretinopathy[4].Inaddition
to the established risk factors, genomic linkage analysis sug-
gestsevidenceforageneticpredispositiontodevelopdiabetic
retinopathy [5]. It is clear that breakthrough treatment op-
tions and targeted intervention approaches are needed to
make inroads into the treatment of this devastating disease
that threatens a growing number of diabetics.
2.Current Pharmacological Options to Combat
AngiogenesisinDiabeticRetinopathy
Anti-VEGF-Atherapeuticshasbecomeadominantapproach
for the management of ocular neovascular diseases [6, 7].
Ongoing clinical trials for diabetic retinopathy predomi-
nantlyfocusonamechanismofactionmediatedviaVEGF-A
antagonism. Of the 103 currently open NIH-sponsored2 Journal of Ophthalmology
clinical trials involving diabetic retinopathy, the majorities
are aimed at treatment of diabetic macular edema and pro-
liferative diabetic retinopathy using Lucentis (ranibizumab),
Avastin (Bevacizumab), and to a lesser extent Macugen
(pegaptanib) either as sole agents, in combination with other
pharmacological agents, or in combination with laser photo-
coagulation therapy (Table 1).
Within the past seven years, two drugs targeting VEGF
were approved for combating ocular neovascularization.
Both these drugs, Macugen (pegaptanib) and Lucentis
(ranibizumab) were approved for exudative age-related mac-
ular degeneration. More recently, Lucentis has received ap-
proval for use in patients suﬀering visual impairment due to
macular edema secondary to central and branch retinal vein
occlusion [8, 9]. The anti-VEGF monoclonal antibody drug
Avastin is currently used oﬀ-label for wet macular degenera-
tion.
The success of anti-VEGF treatments has produced an
unprecedented understanding of the factors and pathogenic
mechanisms operant in several retinal neovascular diseases
andhasdemonstratedthattherapeuticagentsconsideredini-
tially only in the realm of anticancer agents have demon-
strated eﬃcacy in combating ocular neovascularization.
Could a similar story be on the horizon for mTOR inhibitors
for which the principal indication has also been in the treat-
ment of cancers?
Other antiangiogenic approaches for ocular angiogenic
diseases involve growth factors (GH, IGF-1), steroid com-
pounds, or kinase inhibitors (PKC, Src). No mTOR inhib-
itors which target the mammalian target of rapamycin are
currently being clinically evaluated for their eﬃcacy in non-
proliferative or proliferative stages of diabetic retinopathy.
Only two mTOR compounds, Sirolimus (MacuSight, Union
City, Calif, USA) and Palomid 529 (Paloma Pharmaceuticals,
Inc. Jamaica Plain, Mass, USA) are currently being evaluated
in NIH-sponsored trials for ocular indications. Sirolimus is
being evaluated to treat diabetic macular edema which is a
frequent manifestation of diabetic retinopathy, for ARMD,
and for uveitis. Palomid 529 is being evaluated for ARMD
[6, 10]. The current review presents the rational basis for
the utility of mTOR inhibitors in addressing some of the
known pathophysiological events that occur during the early
development and late stage progression of diabetic retinopa-
thy and how the mTOR inhibitors could be a potentially eﬃ-
cacious option in the management of diabetic retinopathy.
3. Involvement of the Phosphatidylinositol-
3-kinase/AKt/Mammalian Target of
Rapamycin(PI3K/Akt/mTOR) Pathwayin
HyperglycemicVasculopathy
An active PI3K/Akt pathway has been linked to glucose dys-
metabolism in retinal tissue. The direct eﬀect of high glucose
on retinal endothelial cells imparts a promigratory phe-
notype with increased ﬁbronectin and alpha (v) beta-(3)
integrin expressions which appears to be concomitant with
the activation of PI3K/Akt pathway [11]. Elevated glu-
cose levels cause decreased uptake of 2-deoxyglucose as
a consequence of downregulated expression of GLUT-1
transporter. The dysmetabolism of glucose utilization and
downregulation of GLUT-1 are mediated by the PI3K and
Akt pathways since pharmacological inhibition of PI3K and
Akt preserved GLUT-1 expression [12].
Experimental ﬁndings [13] suggest that Akt interaction
with RhoB may subserve endothelial cell survival during vas-
cular development and perhaps pathological angiogenesis
leading to the microangiopathies characteristic of diabetic
microvascular disease. It can be surmised that the inhibition
of the PI3K/Akt/mTOR pathway that disrupt the Akt-RhoB
interaction could promote endothelial cell death. Preven-
tion of endothelial cell proliferation and enhancement of
endothelialcellapoptosiscouldserveasatreatmentmodality
to delay or prevent progression of vasculopathies observed in
diabeticretinopathysincethephenotypeofenhancedmigra-
tion of endothelial cells is a requirement for neovasculariza-
tion to occur.
The in vitro ﬁnding that the mRNA and protein expres-
sionoftheanti-angiogenicfactorPEDFisreducedbyglucose
as well as insulin raises interesting implications for the dia-
betic retina. These common physiological metabolites are
elevated in type 2 diabetics, and it has been shown that these
metabolites are dependent on the mTOR pathway for their
destabilizing eﬀect on PEDF [14]. Therefore, mTOR inhibi-
tion may stabilize PEDF mRNA along with protein expres-
sion levels and promote an anti-angiogenic milieu in the
diabetic retina.
4.Signiﬁcanceof HIF-1α,VEGF,and
mTOR Inhibition in Preproliferative
DiabeticRetinopathy
The DCCT study highlighted a transient “early worsening”
eﬀectthat occurs during acute management of diabetics with
retinopathy[15].Invitrostudiesinvestigatingtheunderlying
mechanistic factors responsible for the occurrence of early
worsening suggest that the phenomenon appears to stem
from a hypoxic retina as a consequence of compromised reti-
nal hemodynamics in conjunction with low-glucose avail-
ability[16].Thehypoxiaisexacerbatedbyanacutereduction
of available glucose due to the “tight” glucose control. Inten-
sive lowering of glucose by insulin could result in insuﬃcient
glucose to meet retinal metabolic requirements. Concomi-
tantly, the acute intensive insulin treatment could induce
HIF-α expression via PI3K-dependent pathway [17].
HIF-1α is a principal regulator of VEGF expression. The
binding of HIF-1α to the VEGF hypoxia-responsive elements
promoter evokes signaling via MAPK, PI3K, and JNK path-
ways with a resultant increase in VEGF expression. The Src
kinase pathway leads to VEGF-mediated retinal vascular
availability and breakdown of blood-retinal barrier that may
be observed in diabetes [18]. An increase in permeability of
the endothelium in diabetes involves VEGF in conjunction
with PKC activation. VEGF promotes the phosphoryla-
tion of the tight-junction complex protein occludin via a
PKC-dependent pathway [19]. Further evidence for the
central involvement of VEGF is the observation that VEGFJournal of Ophthalmology 3
Table 1: Number of open NIH trials by indication.
Non-proliferative phase of
diabetic retinopathy
Proliferative phase of
diabetic retinopathy Diabetic macular edema Other∗
Anti-VEGF agents
Avastin 2 6 12 VH (1)
Lucentis 2 7 16 ARMD (3); RVO (1); rubeosis
(1)
Macugen 1 3 Uveitis (1)
Anti-inﬂammatory agents
Bromfenac 1
Dexamethasone 1 1
Diclofenac 1
Ketorolac 1 2
Minocycline 1
Nepafenac 1 2
Triamcinalone 1 7
mTOR inhibitors
Palomid 529 ARMD (2)
Sirolimus 1 ARMD (1); uveitis (1)
Laser therapy
Micropulse 2
Pan laser 4 8 4
PASCAL laser 4 4 2
∗VH: vitreous hemorrhage, ARMD: age-related macular degeneration, RVO: retinal vein occlusion, Note: a particular trial can have more than one indication
or therapeutic agent under investigation.
immunoreactivity is correlated with vascular leakage of mac-
romolecules in human diabetic retinas [20]. Additionally,
chimeric antibodies that sequester VEGF bioavailability
(“VEGF-trap”) reduce vascular leakage as demonstrated by
reductioninextravasationofEvansbluedyeintheretina[21,
22]. An increased VEGF level promotes an acute breakdown
of the blood-retinal barrier that clinically manifests as retinal
edema and exudates in diabetic patients. The breakdown of
the blood-retinal barrier accounts for the clinical manifesta-
tions of “early worsening” eﬀect in patients with minimal to
moderate retinopathy.
The mTOR inhibitors have the potential to suppress the
occurrence and or severity of the transient “early worsening”
eﬀect by helping to avert breakdown of blood-retinal barrier
by modulating HIF-1α-mediated downstream activation of
growth factors, such as the transcriptional regulation of re-
tinal VEGF. The timing of this intervention would precede
the development of irreversible structural damage to the re-
tinal microvasculature and could have a profound eﬀect in
curtailing future deleterious events and perhaps delay or
prevent the progression of retinal microangiopathies.
5. LinkbetweenInﬂammation, Oxidative
Stress, PI3K/Akt/mTOR, andProgressive
DiabeticRetinopathy
Thenaturalhistoryofdiabeticretinopathysuggeststhatboth
chronic inﬂammatory and oxidative stress components ap-
peartobeoperantinthedevelopmentofprogressivediabetic
retinopathy [23]. Using gene-chip array technology applied
to samples from streptozotocin-induced diabetic rats, the
upregulation of several genes integral to inﬂammation, oxi-
dative stress, apoptosis, TGF-β-signaling cascade, and addi-
tional genes related to vascular turnover of retinal blood ves-
sels has been demonstrated [24]. In the diabetic retina, AGE
modify proteins promote oxidative stress and increase in-
ﬂammatory cytokines that alter vascular function [25].
Microglial-mediated release of TNF-α and IL-1β is a mech-
anism by which a pro-inﬂammatory environment exists in
the diabetic retina and contributes to the development of
experimental diabetic retinopathy. Lipid-soluble tetracycline
class of antibiotics that attenuate TNF-α and NF-κB suppress
downstream inﬂammatory mediators and pro-apoptotic sig-
nals derived from activated retinal microglial cells [26].
An increasing body of evidence suggests that a localized
inﬂammatoryprocessthatresideswithintheretinaisintegral
to the early development of diabetic retinopathy. This in-
ﬂammatory process results in a local increase of iNOS,
NF-κB, IL-1β, cytokines, caspases, COX-2, PGE2, the adhe-
sion molecule intercellular adhesion molecule (ICAM-1),
VEGF, and increased permeability and leukostasis within the
retina [27].
The characteristic microangiopathy that develops in dia-
betic retinopathy is linked to localized inﬂammation. An
early hemodynamic change observed in the diabetic retina
of animal models and humans is an increase in leukostasis
and increased expression of cell adhesion molecules such as
ICAM-1 and P-selectin [28]. Mice deﬁcient in TNF-alpha
exhibit extensive reduction in leukocytosis in the retinal4 Journal of Ophthalmology
vessels suggesting that the pro-inﬂammatory cytokine con-
tributes to the leukostasis triggered by platelet-activating fac-
tor, IL-1β, and VEGF [29]. Evidence that leukostasis in dia-
betic retinopathy is linked to oxidant stress and other down-
stream mediators comes from the observation that alpha-
lipoic acid abrogates increases in leukocyte adhesion while
other mechanisms, linked to PKC pathways, are responsible
for hemodynamic alterations that occur concomitantly with
leukostasis [30].
In a diabetic nonhuman primate model, the elevated cir-
culating numbers of polymorphonuclear leukocytes in the
retinal microvasculature have been topographically corre-
lated with regions of capillary occlusion [31]. These alter-
ations are believed to contribute to progressive microan-
giopathythatincludesvascularocclusionandregionsofnon-
perfusion that could make the retina susceptible to hypoxia.
It is feasible that the microangiopathy that appears to be
partly inﬂammation dependent is facilitated by the pro-in-
ﬂammatoryisoformsofVEGF.Ithasbeendemonstratedthat
VEGF is chemotactic to monocytes and upregulates ICAM-1
expression, promoting leukostasis [32]. It has been proposed
that the pathological neovascularization present in diabetic
retinopathy requires the induction of inﬂammation and
leukocyte adhesion to the vessel wall mediated by VEGF-164
isoform [33]. This pro-inﬂammatory milieu appears to be a
prerequisite for induction of the early and potentially pro-
gressive pathogenesis of diabetic retinopathy.
Oxidative stress mechanisms and reactive oxygen species
have been implicated in the pathophysiology of diabetic re-
tinopathy.Theactivationofthesepathwaysleadstoincreased
mitochondrial superoxide production in endothelial cells
and trigger inﬂammatory mediators and dysregulated an-
giogenesis [34]. Poly(ADP-ribose) polymerase (PARP) is in-
volved in oxidative-stress pathways activated during diabetic
retinopathy. In diabetic animal models, PARP is linked to
hypoxia-inducedVEGF overexpression,andPARPinhibitors
are able to prevent VEGF overexpression by a posttransla-
tional mechanism [35]. Oxidative stress has been linked to
apoptosis of retinal pericytes by the induction of the highly
reactive oxoaldehyde, methylglyoxal [36]. Additionally, the
pericytes of diabetics demonstrate increased NF-κB, and it
is surmised that hyperglycemia activates NF-κB and induces
apoptosis of retinal pericytes [37].
Recent evidence have suggested that high glucose modu-
lates TGF-β signals in mesenchymal cells linked to Ca(2+)/
PKC/MAPKs as well as PI3K/Akt/mTOR signal pathways
[38]. The interrelationship between TGF-β,p e r i c y t e s ,a n d
the maintenance of a quiescent retinal endothelial cell has
previously been evaluated [39]. A subpopulation of pericytes
expresses the growth factor TGF-β1, and cross-talk signaling
with the endothelial cell enhances the expression of VEGFR1
on endothelium imparting a protective eﬀect on the vascula-
ture from oxidative damage [40]. The involvement of mTOR
signaling in pericytes could have implications with regards
to the angiogenic mechanism(s) that might be involved in
pericyte biology and would be of profound relevance during
early subclinical stages of diabetic retinopathy.
Loss of pericytes is one of the earliest histopathological
lesions as well as a unique feature of diabetic retinopathy
[41]. Reactive oxygen species (ROSs) can indirectly activate
and promote the nuclear translocation of the pro-inﬂam-
matory transcription factor NF-κB via the degradation of
the negative regulator IkB-α in cytoplasm. The activation of
NF-κB leads to translocation into the nucleus where it binds
to DNA and modulates the expression of various genes
controlling the inﬂammatory process [42]. Elevated PARP
also plays a role in the occurrence of early stage diabetic
microangiopathy, suchasacellularityandpericytedegenera-
tion. Theproposed mechanismis via theactivationof NF-κB
andtheconsequencesofinitiatingdownstreameﬀectorssuch
as ICAM-1 which leads to leukostasis [43].
The mTOR inhibitors could exhibit beneﬁcial eﬀects for
diabeticretinopathybysuppressingapro-inﬂammatoryphe-
notype and modulation of redox sensitive pathways. Sup-
pression of NF-κB by PI3K/Akt-1/mTOR pathway inhibition
would have a pronounced regulatory inﬂuence on the in-
ﬂammatory cascade by promoting a generalized anti-
inﬂammatory eﬀect. Some of the mTOR inhibitors, such as
rapamycin, have an established immunosuppressive eﬀect.
Although this can impart an unfavorable side eﬀect proﬁle,
it can be an advantageous attribute if it can be used to
suppress the pro-inﬂammatory phenotype that exists in
diabetes. The immunomodulatory attribute of mTOR inhi-
b i t i o nc o u l db eu s e dt os u p p r e s sN F - κB expression, which
would reduce the expression of downstream pro-inﬂam-
matory mediators such as monocyte chemoattractant pro-
tein (MCP-1), VEGF, TNF-α,I L - 1 β, RAGE, ICAM-1, and
vascular cell adhesion molecule (VCAM-1) that are under
the regulatory inﬂuence of NF-κB. These pro-inﬂammatory
cytokines, chemokines, and adhesion molecules have been
demonstrated to play a role in the development and pro-
gression of diabetic retinopathy [44]. Suppression of TNF-α
byomega-3-polyunsaturatedfattyacidsreducesangiogenesis
in a mouse model of oxygen-induced retinopathy as well as
implicated in diabetic retinopathy [45]. Thus, NF-κBi sa
mediator for cytokine-induced inﬂammatory responses by
serving as a central convergent regulator that increases the
release of cytokines and other chemotactic factors operant in
inﬂammation.
6. SigniﬁcanceofPI3K/Akt/mTORInhibitionin
ProliferativeDiabeticRetinopathy
An indication suggesting that the inhibition of PI3K/Akt/
mTOR pathway could have beneﬁcial therapeutic eﬀects for
the management of proliferative diabetic retinopathy stems
from the ﬁndings that growth factors known to play major
roles in the induction of angiogenesis depend on PI3K/Akt/
mTOR for prolonging the cell survival signals that are oper-
ant in pathological angiogenesis [46]. The proliferative stage
of diabetic retinopathy is ischemia driven in which the hyp-
oxia ampliﬁes the proliferative component of angiogenesis.
Signaling via mTOR pathway has been shown to augment
mitogen-stimulated vascularcellproliferationandangiogen-
esis in response to hypoxia [47]. The signaling mediated thru
mTORplaysamajorroleinhypoxia-inducedsmoothmuscle
and endothelial cell proliferation. Tissue hypoxia modulates
HIF-1α hydroxylation and regulates its protein and activityJournal of Ophthalmology 5
levels [48]. HIF-1α induces the expression of various growth
factors and genes such as VEGF, VEGF ﬂt-1 receptor, bFGF,
PDGF, nitric oxide synthases, angiopoietin 2, and IGF-1
that are established inducers of neovascularization. In ocular
tissue, it has been demonstrated that the proangiogenic ef-
fects of IGF-1 are mediated via up-regulated VEGF expres-
sion obtained by activation of the PI3K/Akt/mTOR pathway
and posttranscriptional activation of HIF-α [48]. It has been
demonstrated that mTOR pathway inﬂuences the mecha-
nism on how the same growth factor, such as IGF-1, can
exhibit divergent pleiotrophic eﬀects in an HIF-1α-depend-
ent manner [49]. For instance, IGF-1 can mediate VEGF
expression by mechanisms dependent as well as independent
ofHIF-1α,including stressandcytokine-inducedVEGFpro-
duction [50, 51]. Furthermore, transgenic mice overexpress-
ing IGF-1 in the retina develop vascular alterations that re-
semble human diabetic retinopathy [52].
Both placenta growth factor (PIGF) and VEGF increase
Akt phosphorylation and activate downstream substrates.
Experimental blockade of PI3K signal and activation by over
expression of adenovirus-mediated phosphatases that dis-
rupt Akt phosphorylation also disrupt angiogenesis. There-
fore, several growth factors that have demonstrated a role
in the development of the vasculopathy characteristic of hu-
manproliferativediabeticretinopathyarelinkedtothePI3K/
Akt/mTOR pathway for the regulation of their expression
and activity. The mTOR pathway has also been implicated
in other pathobiology of the retina. The dediﬀerentiation of
RPE and subsequent photoreceptor degeneration is associ-
ated with mTOR activation. The inhibition of mTOR path-
way is able to suppress RPE dediﬀerentiation as well as pres-
ervation of photoreceptor functionality in mice [53].
The recognition that oxygen levels regulate mTOR func-
tion and that mTOR is involved in hypoxia-facilitated vaso-
proliferative responses proposes a relatively novel down-
stream functional link between hypoxia and mitogenic sig-
naling involved in proliferation of vascular cells [47]. These
collective observations suggest that PI3K/Akt/mTOR path-
way inhibition would be suited to manage the advanced pro-
liferativestagesofdiabeticretinopathywherehypoxia-driven
vasoproliferative mechanisms predominate in contributing
to the vasculopathy.
7.PI3K/Akt/mTOR Inhibitorsas
Potential Therapeutics
The inhibition of the PI3K/Akt/mTOR pathway is an attrac-
tive therapeutic target for diabetic retinopathy because func-
tionally it is a convergent pathway for a variety of growth
factors, pro-inﬂammatory mediators, and downstream sub-
strates that are regulators of cellular survival processes essen-
tial to the initiation and progression of the angiogenic cas-
cade (Figure 1). Novel ﬁndings regarding the regulation of
VEGF expression in the retina of rodents suggest that hyper-
glycemia induces VEGF protein expression via eukaryotic
initiation factor-4E (eIF4E) and its binding proteins (4E-
BP1&2) [54]. Mice null for these proteins did not exhibit
increases in VEGF protein initiated by hyperglycemia. The
eIF4E and 4E-BP1 proteins are downstream eﬀectors of the
regulatory mTOR complex 1 (mTORC1), thereby, implicat-
ing a functional role of this pathway in the pathobiology of
diabetic retinopathy.
Several inhibitors of the PI3K superfamily have been de-
scribed [55]. The pharmacologic agents LY294002 and wort-
mannin both target the p110α catalytic subunit of PI3K [56].
Perifosine and PX-866 are lipid-based Akt inhibitors that
prevent translocation to the membrane while phosphatidyli-
nositol ether analogs (PIAs) bind to the PH domain of PDK-
1. Triciribine (API-2) is selective for Akt-2 inhibition [56].
Targeting proximal pathway components generally result in
broad inhibition of downstream signaling cascade and may
augment undesirable side eﬀects.
Clinically marketed compounds that modulate a more
downstream pathway component are mTOR complex in-
hibitors and include TORISEL, Aﬁnitor, and Rapamune
(rapamycin). The best characterized mTOR complex in-
hibitor is rapamycin, “a macrolide antifungal compound
produced by the soil bacterium Streptomyces hygroscopicus
isolated from the soil of Rapa Nui (Easter Island)” [55].
Rapamycin interacts with FK506-binding protein and in-
hibits the activity of TORC1 with extremely high selecti-
vity [55]. Intraperitoneal administration of rapamycin has
demonstrated anti-angiogenic eﬃcacy in mice with laser-in-
duced choroidal neovascularization and in oxygen-induced
retinopathy [57].
An abbreviated summary of some principal of Akt, and
ﬁrst- and second-generation mTOR inhibitors that have ad-
vanced to various stages of clinical development along with
selected naturally occurring agents with pending prospects
for medical indication are summarized in Table 2.
8.Pitfalls,Limitations,andProgressof
mTOR Inhibitors
Toxicities associated with various mTOR inhibitors that are
particularly pertinent to diabetics include gastrointestinal
eﬀects, hematological, decreased glucose tolerance, hyper-
glycemia, and hypertriglyceridemia. These eﬀects may stem
from the involvement of this pathway in the regulation of
hexokinase and glycolysis leading to deregulation of glucose
andlipidhomeostasis[58].I nr oadsc ontin uet obemadeint o
the mechanistic understanding of some of the more preva-
lent side eﬀects that have been demonstrated with mTOR
inhibitors [59]. The included summary Table 3 highlights
many of the reported adverse eﬀects of several mTOR in-
hibitors from a variety of clinical and preclinical studies [60–
65]. The adverse eﬀects are manifested in many organ sys-
tems with diﬀerentincidencerateanddurationofdrugtreat-
ment when administered for systemic exposure. The percent
incidence and duration of treatment, when reported as a
range in the table, are a compilation from several diﬀerent
studies. Almost all adverse eﬀects are manageable with ap-
propriate clinical intervention or fully reversible upon the
discontinuation of the drug. Early reported adverse eﬀects
involve cutaneous lesions and oral ulcerations [66–69]. With
more prolonged drug use, metabolic [70–72], hematological
alterations [73, 74], and renal toxicities [75, 76]c a nb e c o m e
evident but are generally manageable. Of greatest clinical6 Journal of Ophthalmology
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Figure 1: Schematic of the PI3K/Akt/mTOR Pathway. pathway highlights downstream eﬀectors pertinent to the development of diabetic
retinopathy along with the beneﬁt of dual inhibitors of mTOR (TORC1 and TORC2) that prevent feedback activation and prevent
downstream eﬀectors that are detrimental in the progression of diabetic retinopathy. References consulted for Figure 1:[ 56], Paloma
Pharmaceuticals presentation ﬁles, and Angioceutics International.
concern is the development of noninfectious pneumonitis
which requires careful monitoring and clinical intervention
[77, 78]. One study has reported a high incidence of revers-
ible infertility [79].
The potent anti-angiogenic eﬀects of mTOR inhibitors
canhavedeleteriouseﬀectswhenthereistherequirementfor
physiological processes that are dependent on angiogenesis,
such as cutaneous wound healing, menstruation, bone
growth, and remodeling of bone following fractures. The
inhibition of mTOR pathway could lead to delays in wound
healing perhaps linked to modulation of immune responses
[80–82]. In murine bone fracture models, Rapamycin has
been shown to delay callus formation and reduce biome-
chanical bone strength during the healing process, but with-
out appreciable detriment to the bone after the period of
healing [83]. A special concern arises in the treatment of
young children because experimental studies have shown
that rapamycin can inhibit vascularization at the epiphyseal
plate of long bones resulting in stunted growth in rats [84].
However, it is rare for this age group to develop diabetic
retinopathy andthereforenot alikelypatient population that
would be of concern for this mode of therapy.
Many potential side eﬀects can be avoided by temporary
cessation of drug administration during periods for which
the patient has special transient considerations. Careful
monitoringmustbegivenwhentreatingpatientsintheacute
phase of wound healing, in diabetics with a heightened risk
for the development of foot ulcers, and those with bone
fractures. Based on our current understanding of the mTOR
pathway’s role in wound healing, it would appear prudent
that early and close monitoring and perhaps even transient
discontinuation of drug treatment is warranted in cases
where patients are experiencing an active resolution of a cu-
taneous wound or other physiological healing processes that
are angiogenic dependent. The implementation of careful
patient counseling and adaptive drug regiment plan should
beeﬀectiveinminimizingorpreventingthismanageableside
eﬀect component of mTOR inhibitors.
As we acquire a greater understanding of the mechanistic
basis for the associated side eﬀects with this class of drugs, it
will expand the therapeutic utility and diversify the potential
medical applications such as for the management of diabetic
retinopathy.Journal of Ophthalmology 7
Table 2: Principal PI3K/Akt/mTOR Inhibitors in clinical development.
Name and general classiﬁcation Manufacturer or source Clinical stage Indication
Akt inhibitors
SF1126 (RGD peptide +
LY294002 a morpholino
derivative of quercetin)
Semaphore Pharmaceuticals Phase 1 Chronic lymphocytic leukemia
Perifosine (KRX-0401) Keryx Biopharmaceuticals, Inc Phase 2 and Phase 3
Colorectal cancers; multiple
myeloma; other multiple cancer
types
PX-866 Oncothyreon Phase 1 & 2 Solid tumor disease;
Glioblastoma
Triciribine (API-2; TCN-PM;
VD-0002) VioQuest Pharmaceuticals Phase 1 p-AKT-positive solid
malignancies
Rapamycin (and analogs)
Everolimus (RAD001; Zortress;
Aﬁnitor) Novartis Pharma AG Marketed 2009
Advanced renal cell carcinoma
after failure with sunitinib or
sorafenib; subependymal giant
cell astrocytoma (SEGA)
Deforolimus (AP23573;
MK-8669; Ridaforolimus) ARIAD Pharmaceuticals; Merck Phase 3 (SUCCEED TRIAL) Metastatic soft-tissue and bone
sarcomas
Sirolimus (Rapamycin; MSR001;
Rapamune; Perceiva)
Santen Inc; MacuSight,
Inc.Wyeth Pharmaceuticals November 2010
Prophylaxis of organ rejection in
patients >13 years old receiving
kidney transplant
Temsirolimus (CCI-779;
TORISEL) Wyeth Pharmaceuticals Marketed 2007 Advanced renal cell carcinoma
Dual mTOR inhibitors
AZD8055 Astra Zeneca Multiple Phase 1 and multiple
Phase 2
Advanced hepatocellular
c a r c i n o m a ;a d v a n c e ds o l i d
malignancies and lymphomas
NVP-BEZ235 Novartis Pharma AG Pancreatic cancer
WYE-125132 Wyeth Pharmaceuticals Multiple Phase 1 and Phase 2 Advanced malignancies
Palomid 529 Paloma Pharmaceuticals Inc. Phase 1
Age related macular
degeneration (intravitreal and
conjunctival administration)
PKI-179 Pﬁzer; Wyeth Phase 1 Advanced malignant solid
tumors
PKI-402 Pﬁzer
PKI-587 (PF-05212384) Pﬁzer Phase 1 Incurable cancer
Natural mTOR inhibitors
Epigallocatechin gallate (EGCG)
(ﬂavonoid polyphenol) Green tea Pre-clinical Pending
Caﬀeine Multiple and varied Pre-clinical Pending
Celastrol Thunder of God vine
(Tripterygium wilfordii) Pre-clinical Pending
Curcumin (diferuloylmethane) Indian spice turmeric Pre-clinical Colon cancer (?)
Hispidulin (ﬂavonoid molecule) Artemisia vestita Saussurea
involucrate Pre-clinical Pending
Resveratrol Skin of red grapes Pre-clinical Pending
∗Note references used to compile table include: Drugs.com, Searchmedica.com, Clinicaltrials.gov, PubMed.gov, and FDA product information inserts when
available.
9. Therapeutic Potential of Second-Generation
mTOR Inhibitors
The PI3K/Akt/mTOR pathway has proximal and distal feed-
back signaling and although mTOR is downstream eﬀector
of Akt, the mTOR complex 2 (TORC2) can phosphorylate
Akt which then activate Akt via a feedback mechanism [85].
Rapamycin and early spin-oﬀ analogs (rapalogs) mTOR in-
hibitors had the limitation that they did not aﬀect mTORC2;
consequently, duration of inhibition was shortened due to8 Journal of Ophthalmology
Table 3: Reported adverse eﬀects of mTOR inhibitors.
General
disorder
classiﬁcation
Speciﬁc adverse event Reported percent
incidence
Duration
on Meds
(days)
Agent Clinical management
options Outcome
Cutaneous Delayed wound healing Multiple mTOR
inhibitors Manageable
Skin rash Ridaforolimus Manageable
Spongiotic dermatitis
with eosinophils 14 Temsirolimus Clobetasol Resolution
Hematological Thrombocytopenia 8–22.7 Everolimus and
sirolimus Interleukin 11 Manageable
Anemia (microcytic) 9–20
Temsirolimus
and everolimus
and sirolimus
Erythropoietin Manageable
Leukopenia 18.2 Everolimus and
sirolimus
Colony stimulating
factor Manageable
Hepatic Transaminase Elevations 10 Everolimus Periodic liver function
tests
Alkaline phosphatase
elevations 8 Everolimus Periodic liver function
tests
Immunological Severe infections 2.3
Metabolic Hypercholesterolemia 50 Sirolimus and
everolimus Statin therapy Manageable
Hypertriglyceridemia 31.8 Sirolimus and
everolimus Fibrates Manageable
Hyperglycemia 11 temsirolimus Glucose lowering agents Manageable
Fatigue 11 Temsirolimus
Hypophosphatemia 5 Temsirolimus
Hyperlipidemia 5 Everolimus Lipid lovering drugs
Oral Ulcerations 66 5 Deforolimus Discontinuation Reversible
Mucositis 6 Discontinuation Reversible
Aphthous stomatitis 6 Discontinuation Reversible
Pulmonary Noninfectious
pneumonitis 4.8–18 60–1500 Sirolimus and
everolimus
Withdrawal, antibiotics
and steroids Reversible
Dyspnea 9
Grade 1 (asymptomatic) 3.3 Everolimus Reduction Reversible
Grade 2 (Ok daily living) 6.6 Everolimus Withdrawal Reversible
Grade 3 ( oxygen
indicated) 3.6 Everolimus Withdrawal, antibiotics
and steroids Reversible
Grade 4 (life
threatening) 0 Everolimus None
Renal Proteinuria 1.6–4.1 540–1500 Sirolimus and
everolimus Withdrawal Reversible
Proteinuria (grade 3 to
4) 25 273 Bevacizumab +
everolimus Discontinuation Reversible
Reproductive Infertility (oligospermia) 66.6 150–360 Sirolimus Discontinuation Full recovery
amenorrhea 14.2 150–360 Sirolimus Discontinuation Reversible
feedback activation of Akt, The mechanism by which “ra-
palogs” selectively inhibit mTOR complex 1 (TORC1) has
been elucidated in detail and involves mTORC1-dependent
phosphorylation of 4E-BP1 and S6K1 through distinct
mechanisms [86]. Rapamycin, perhaps as a consequence of
feedback activation of Akt via TORC2, has exhibited a para-
doxical increase in VEGF and Flt-1 protein levels in response
to pathway inhibition. This feature would appear to be prob-
lematic for the long-term management of diabetic retinopa-
thy. This feedback loop diminishes the extent of pathway
blockade and has resulted in limited eﬃcacy of these thera-
peutic agents in the past. However, newer generation mTOR
inhibitors do not present this potentially detrimental feed-
back issue.Journal of Ophthalmology 9
A successful approach to drug design that circumvents
the limitations of previous mTOR inhibitors due to feedback
activation of Akt has been developed. Selective and potent
novel inhibitors of mTOR which exhibit dual inhibition of
mTORC1 as well as mTORC2 have demonstrated high eﬃ-
cacy in preventing feedback-loop activation of the pathway
and rendered improvements in outcome measures. The so-
phistication of the armamentarium of drugs now available
include highly speciﬁc mTOR inhibitors, dual PI3K/mTOR
inhibitors [87], as well as AKT inhibitors that may possess
ATP-competitive or ATP-independent allosteric modulators
[88].
Technological breakthroughs in drug design continue to
improve the approach to target both PI3K and mTOR path-
ways via hybrid inhibitors such as diester-linked conjugates
capable of bridging two inhibitors in combination, with the
potential to enhance eﬃcacy [89]. Dramatic improvements
in mTOR-targeting speciﬁcity and selectivity continue to be
achieved by molecular modeling and synthetic chemical
methods [90].
Although an extensive inclusion of the various types of
mTOR inhibitors is beyond the scope and main focus of this
review,therearenumerousexcellentreviewarticlesavailable.
The interested reader is referred to those articles for further
informationregardinggeneraloverviewsofmTORinhibitors
[91–93], emphasis on development of dual mTOR inhibitors
[94–96], functional consequences of mTOR inhibition [97],
mTOR inhibitors in clinical development [98, 99], and dis-
cussion of some natural mTOR inhibitors [100]. Green Tea
[101] and epigallocatechin gallate (EGCG) [102], both natu-
ral mTOR inhibitors, have been shown to impart protective
eﬀects in diabetic retinopathy. However, the beneﬁt that is
derived from green tea and EGCG appears to be predomi-
nantlymediatedbytheirpotentantioxidativeproperties.The
polyphenol resveratrol also has mTOR-modulating proper-
ties and has exhibited cytoprotective eﬀects and inhibition of
VEGF secretion in human retinal ARPE-19 cells [103]. The
beneﬁt to diabetic retinopathy stemming from these com-
pounds that may be attributable to the ancillary eﬀect of in-
hibitionofthemTORpathwayhasnotbeendocumentedand
remains to be elucidated.
Of the two mTOR inhibitors in NIH clinical trials for
ocular indications (Tables 1 and 2) neither is targeting dia-
betic retinopathy per se as an indication although preclinical
data strongly suggest that they possess varied pharmacologi-
cal features that would make them eﬃcacious candidates for
treatment of diabetic retinopathy. One of these inhibitors,
Sirolimus (Perceiva), has recently completed (January 29,
2011)afast-trackdesignatedNIHsponsoredpilotstudywith
ﬁve participants to evaluate treatment option for diabetic
macular edema. The primary outcome measure is changed
in visual acuity at six months relative to baseline. Final data
collection has been completed, and results are eminently
pending. Separate Phase 2 studies evaluating Perceiva for
neovascular AMD and dry eye syndrome are also pending.
Limitations that may confront Perceiva as a clinical agent are
the reported immunosuppressive eﬀects and that the anti-
angiogenic eﬀects are predominantly cytostatic rather than
anti-angiogenic or angiolytic.
The other inhibitor, Palomid 529, a small molecule syn-
thetic non-steroidal compound with a chemical structure
derived from dibenzo[c]-chromen-6-one, is a ﬁrst-in-class
allosteric dual mTORC1 and mTORC2-dissociative inhibitor
that abrogates compensatory feedback loop activation. The
mechanism of action is unique in that it dissociates the var-
ious proteins in the mTORC1/C2 complex rather than in-
hibitingviacatalyticcompetitiveinhibition.Thispresumably
imparts broader inhibitor activity. Palomid 529 has had ex-
tensive characterization of preclinical pharmacokinetic,
biodistribution, and eﬃcacy testing involving ocular studies.
Muller cell proliferation and glial scar formation is reduced
following experimental retinal detachment in a rabbit model
using Palomid 529 [104]. The safety proﬁle for Palomid 529
is excellent without apparent adverse eﬀects. Concentrations
of the drug remain detectable in the retina and choroid for
at least six months after last dosing. Therefore, the frequency
for repeat subconjunctival or intravitreal administration is
minimized along with the risk of iatrogenic ocular complica-
tions.
Clinically relevant adverse events have been experienced
with the use of TORC1 inhibitors, Sirolimus, and its ana-
logs, when administered via systemic administration as de-
scribed in Table 3. However, as retinal therapeutic agents are
routinely administered via a targeted approach, that is, in-
travitreal or subconjunctival, many of these issues would not
be encountered since the local dose of drug administered
would not reach suﬃcient levels in the systemic circulation
to cause toxicities. With Palomid 529, such toxicities have
not been observed to date in its ongoing human Phase I
age-related macular degeneration study where administra-
tion was either intravitreal or subconjunctival (Paloma
Pharmaceuticals,personalcommunication).DualmTORC1/
mTORC2 inhibitors might be expected to eﬀectively induce
completeblockadeofthePI3K/Akt/mTORpathway,asignal-
ing cascade found in all cells necessary for normal homoeo-
stasis, thereby exerting toxic eﬀects. Relative to Palomid 529,
no toxicity was noted in non-GLP or GLP toxicology studies
in dogs and rats when the drug was administered intra-
venouslyatdoselevelswellabovethatwhichhadbeenshown
to exert activity in a variety of animal models of ophthalmic
or oncologic disease [105]. No dose-limiting toxicities were
found when Palomid 529 was administered in a dose-ran-
gingintravitrealnon-GLPorGLPstudiesindogs andrabbits
(Paloma Pharmaceuticals, personal communication). Rela-
tive to Palomid 529, it is possible that its inhibitory eﬀects on
the PI3K/Akt/mTOR pathway are not to induce an absolute
blockade of the pathway, but to reduce its pathological up-
regulation to a normal level. In the oxygen-induced reti-
nopathy model (retinopathy of prematurity model), an
established surrogate animal model for evaluating hypoxia-
induced progressive vasculopathy reminiscent of mecha-
nisms operant in diabetic retinopathy, Palomid 529 inhibited
pathological neovascularization, see Figure 2(a).
In this model, when Palomid 529 is compared head
to head with a murine anti-VEGF antibody, the anti-
VEGF antibody treatment appears to inhibit both patho-
logical and normal angiogenesis while Palomid 529 inhibits
predominantly pathological angiogenesis. This is shown by10 Journal of Ophthalmology
Control Control
Avascular
space
Aberrant
0.5mg palomid 529
0.25mg palomid 529 Palomid (0.25mg /3days)
Palomid (0.5mg /3 days)
neovascularization
Anti-VEGFA (5μg/mouse @ days 12,13))
+ anti-VEGFA (5μg/mouse @ days 12,13)
5μg anti-VEGF
5μg anti-VEGF
(a)
Control
0.25mg
Palomid 529
0.5mg
Palomid 529
Control
-VEGF 5μg × 2d o s e s Anti
Micro-
aneur sm y
Palomid 0.5mg /3 days
-VEGF 5μg × 2d o s e s
and
palomid 0.2
Anti
5mg/3days
5μg anti-VEGF
5μg
anti-VEGF
(b)
Figure 2: Oxygen-induced retinopathy model-retinal ﬂat mount. Seven-day old SV129 mouse pups were put at 70% oxygen for 5 days,
removed to normal air, and injected intraperitoneal with Palomid 529 for 5 days. The animals were then sacriﬁced and the eyes removed and
ﬁxed in 10% formalin for 30min. The retinas were isolated, blocked for 1hr in PBS containing 1% BSA, 1% goat serum, and 0.5% TX-100,
stained overnight with 10μg/mL BS-1 lectin labeled with FITC (Sigma-Aldrich), washed in PBS and ﬂat mounted.Journal of Ophthalmology 11
presence of avascular space around optic nerve in control,
increased with anti-VEGF treatment but essentially lacking
with Palomid 529 treatment. This observation suggests
that the inhibitory actions of Palomid 529 inﬂuencing the
PI3K/Akt/mTOR pathway is mediated by normalizing the
signaling activity level of this pathway rather than promoting
a suppressive blockage leading to subnormal function. In
support of this viewpoint is the observation that neonatal
vascularization in the oxygen-induced retinopathy mouse
pups was not adversely aﬀected and perhaps eases concerns
regarding the induction of adverse events in young patients
when using Palomid 529.
In addition, upon closer inspection at higher magniﬁca-
tion, anti-VEGF antibody did not appreciably inhibit glom-
eruloid formation (“microaneurysms”), while Palomid 529
showed signiﬁcant inhibition of this vascular malformation,
see Figure 2(b).
Palomid 529 has completed 4 of 6 cohorts of the com-
pany’s ongoing intravitreal Phase 1 human age-related mac-
ular degeneration trial. The NEI is also conducting its own
Phase I trial in age-related macular degeneration with sub-
conjunctival administration. Preliminary results in the in-
travitreal study have shown signiﬁcant reduction of retinal
thickness as evidenced by OCT in two of the three patients at
the 4th cohort (0.5 micrograms). Positive data has also been
observed with the NEI trial. The outcome of these trials will
be very instructive with regards to future application of this
drug, other drugs of its class, and to other angiogenic ocular
diseases.
Clinical trial data on safety and eﬃcacy of dual mTOR
inhibitors is emerging, particularly for the treatment of a
variety of cancers. There have been widespread concerns that
the novel dual mTOR inhibitors with their potent capacity
to cause extensive and diﬀu s eb l o c k a d eo fd o w n s t r e a ms i g -
naling will exhibit additional and perhaps unpredictable side
eﬀects beyond what has already become apparent from the
side eﬀect proﬁle of the early generation mTOR inhibitors.
However, from the limited clinical data that has emerged
using dual mTOR inhibitors, the prognostic outlook for the
utility of these agents in providing improved therapeutic
outcomes with reduced tachyphylaxis appears encouraging
[106]. For the treatment of leukemia, the dual mTOR in-
hibitor NVP-BEZ235 has exhibited the potential to act syn-
ergistically to augment the eﬀect of other chemotherapeutic
agents [107] and appears to facilitate bone mineral-matrix
deposition thereby countering the potential for bone loss
with certain tumors [108]. In gliomas, this dual mTOR in-
hibitor has not demonstrated toxicities and exhibits potent
anti-angiogenic eﬀects [109].
10. What Future Frontiers and Direction are
Available for mTOR Inhibitorswith the Aim
toTreatDiabeticRetinopathy?
It has been suggested that mTOR inhibition in the setting of
hyperinsulinemiaandtype2 diabetes wouldbe aparticularly
attractive therapeutic modality [110]. The use of mTOR in-
hibitors in diabetics is suggested despite this class of drugs
inducing alterations in glucose and lipid metabolism, which
can be oﬀset and carefully monitored and corrected with
concomitant glucose-lowering and/or lipid-lowering phar-
macological agents that have good eﬃcacy and low toxicity.
From a drug development standpoint, the PI3K/Akt/
mTORpathwayhaspresentedsome unique challenges[111].
The high degree of evolutionary conservation of the PI3K/
Akt/mTOR pathway across species is a reminder that it sub-
serves a myriad of critical and essential biological functions,
a n da ss u c hi tm u s tb et a r g e t e dw i t hh i g hs p e c i ﬁ c i t yi nt h e
aim of decreasing toxicity. However, the pathway has exten-
siveinteractionswithotherbiologicalpathwaysandissubject
to a rather complex self-regulating negative feedback loop
[111]. The existence of multiple and oppositional regulators
contributes to the complexity on how best to achieve an ef-
ﬁcacious inhibition of pathway signaling. For instance,
rapamycin has exhibited limited eﬃcacy as a consequence
of negative feedback activation of PI3K/Akt in ocular appli-
cations aimed at modulating cellular proliferation in uveal
melanoma [112]. This ﬁnding underscores the future need
for molecules that exhibit dual inhibition of mTORC1/C2
complexes to circumvent limitations imparted by feedback
regulation.
Inordertopreventordelaydrugresistanceandminimize
ancillary side eﬀects of mTOR inhibition, selective dual in-
h i b i t o r so fm T O Rc o m p l e x e sa sw e l la sc o m b i n a t i o nt h e r a p y
withotheragentssuchasVEGFantagonistswillbecrucialfor
the development of new therapeutic options to manage the
complex vasculopathy of diabetic retinopathy. A signiﬁcant
therapeutic opportunity exists in that mTOR inhibitors re-
duce VEGF mRNA stability [113], thereby, providing a ratio-
nal basis to explore whether combination therapy of mTOR
inhibitors and anti-VEGF agents can produce additive or sy-
nergistic beneﬁcial eﬀects in regulating the angiogenic com-
ponent of diabetic retinopathy. Combination of mTOR in-
hibition with VEGF antagonism has demonstrated an aug-
mented eﬀect in suppressing endothelial cell growth in pros-
tatetumorcells[114]andangiogenesisinamodelofoxygen-
induced retinopathy.
Dual mTOR inhibitors capable of synergizing with anti-
VEGF therapeutics that either inhibit a distinct regulatory
site on the same pathway or inhibit a parallel prosurvival
pathway would provide a broader mechanistic intervention
of the angiogenic process. Because mTOR inhibitors have a
direct anti-angiogenic eﬀect, mediated via modulation of
HIF-1α, it may be possible to approach anti-angiogenic ther-
apy from a dual approach in combination with anti-VEGF
monoclonal antibodies (bevacizumab, ranibizumab, and pe-
gaptanib) or VEGF-trap while minimizing the potential for
overlapping toxicities and at the same time selectively target-
ing the operant mechanism(s) in the pathobiology of dia-
betic retinopathy.
Several Phase I studies have investigated the safety proﬁle
of combination therapy using bevacizumab and mTOR
inhibitorssirolimus,everolimus,orthedualmTORinhibitor
WYE-125132 in cancer patients [115–117]. Preliminary
data suggest that combination therapy of these agents is a
feasible therapeutic modality with tolerable side eﬀects. In
general, the prevalence and severity of observed toxicities12 Journal of Ophthalmology
with combination of these drugs were no greater than what
has been observed and associated with each individual drug.
Of therapeutic beneﬁt was the potential to lower the dose
of each individual agent to improve dose-limiting toxicities
over the long run while retaining or even enhancing eﬃcacy
of treatment. Future trials will need to elucidate whether
combination therapy versus serial drug treatment regiment
can also oﬀer an alternative attractive treatment option for
disease management.
An analogous approach can be taken by linking mTOR
inhibitors with other antagonists or agents where the mech-
anism of action targets an alternate pathway, thereby aug-
menting the potential for additive or synergistic outcomes
on eﬃcacy measures. The combinatorial drug approach with
mTOR inhibitors can be extended to be coadministered with
an entire class of anti-inﬂammatory agents as combination
therapy. The mTOR inhibitors in combination with Nepa-
fenac,currentlyinclinicaltrialsfornon-proliferativediabetic
retinopathy and macular edema, would appear to be a
feasible combinatorial-drug approach to combat diabetic
retinopathy. Experimental ﬁndings using topical 0.3% Nepa-
fenac 4x/day in diabetic rats for up to 9 months has demon-
strated reductions in superoxide, cyclooxygenase-2, PGE-2,
and leukostasis and prevention of functional changes in os-
cillatory potential as well as vasculopathy including apop-
tosis, regions of acellularity, and degeneration of pericytes
[118].
The multi-drug approach might provide the therapeutic
advantage that lower doses of each of the combined agents
would be required for eﬃcacy with the beneﬁt of mini-
mizing potential toxicities. This strategy can be justiﬁed on
the evidence that extensive cross-talk of pathways underlie
the angiogenic signaling cascade and that the vasculopathy
innate to diabetic retinopathy involves a myriad of initiators.
Particularly, attractive would be the combinations of mTOR
inhibitors with triamcinalone (Kenacort) or dexamethasone
(Ozurdex) both of which have developed either scleral or
intravitreal sustained drug delivery formulation and ﬁrst-in
class biodegradable device technologies for drug delivery to
the retina.
Several studies have investigated the beneﬁt of combin-
ing mTOR inhibitors with established glucocorticoid anti-
inﬂammatory agents in cancer patients. The mTOR in-
hibitors not only potentiate the apoptotic eﬀect of steroids,
but confer enhanced sensitivity to glucocorticoids, thereby,
potentially allowing sustained eﬃcacious and chronic use
of these drugs in ophthalmology to treat ocular angiogenic
andinﬂammatorydiseaseswithouthavingtoincreasedosage
over time. The clinical utility of glucocorticoids in ophthal-
mology is extensive but is hampered by side eﬀects as well
as the development of glucocorticoid resistance imposing a
limit on the duration of use and clinical utility.
The combined use of rapamycin with dexamethasone
appears to impart the beneﬁt of not developing resistance to
the biological eﬀects of dexamethasone as well as enhancing
the proapoptotic caspase-3 signaling [119]. The molecular
pathway by which mTOR inhibitors are able to augment the
pro-apoptotic eﬀects of glucocorticoids and confer enhanced
sensitivity to dexamethasone in a variety of cell lines has
recently been elucidated. Rapamycin promotes the dissocia-
tion of the Bim-Mcl-1 complex to promote dexamethasone-
induced apoptosis [120] and by antagonizing the eﬀect of
glucocorticoids on the phosphorylation state of 4E-BP1 at
Ser65 and p27 upregulation [121]. The mTOR inhibitor
CCI-779 in combination with dexamethasone also augments
the apoptotic eﬀect of the anti-inﬂammatory agent [122].
The combination of mTOR inhibitors with COX2 inhibitors
promotes a synergistic eﬀect in suppressing tumor angiogen-
esis that allows subtoxic doses of each agent while retaining
eﬃcacy in the clinical management of the disease [123].
Transscleral delivery of triamcinalone and Lucentis has
been successfully applied in animal models using electrically
facilitated macroesis methodology [124]. Dexamethasone
has been shown to suppress the release of various pro-in-
ﬂammatory and pro-angiogenic cytokines from retinal peri-
cytes [125]. Given the prominent role that pericytes play in
theetiologyofdiabeticretinopathy,thiscouldbeasigniﬁcant
novel therapeutic avenue to address the early pathological
changes and inﬂuence disease sequelae. Implants with sus-
tained release of anti-inﬂammatory agents have been suc-
cessfully applied when placed in the suprachoroidal space to
treat uveitis [126]. Biodegradable hydrogels for implantation
in a subconjunctival location have the potential for chronic
periocular delivery of drugs to treat diabetic retinopathy
[127].
11. Multiple Optionsand Opportunitiesto
MinimizeUndesirable SystemicSide Effects
D u et oa n a t o m i c a la n dp h y s i o l o g i c a lb a r r i e r s ,t h ee y ep r e -
sents a myriad of challenges as a target organ for drug deliv-
ery. Recent advances in drug delivery technology including
formulation, polymer chemistry, nanotechnology [128], mi-
crodrug devices [129], and surgical advancements have per-
mitted the exploration of several unique options and oppor-
tunities for topical ocular drug administration. These ap-
proaches expand the usefulness of many drugs to treat ocular
diseases which otherwise would fail to demonstrate eﬃcacy
or would exhibit substantial systemic adverse eﬀects that
would preclude their clinical use. Signiﬁcant advances in
drug delivery methodology have improved drug retention
time, bioavailability, and enhanced trans-scleral or corneal
penetration. These technologies include the use of hydrogels
[130], mucoadhesive polymers [131], cyclodextrins, nano-
composite formulations [132], micellar and lipid nanopar-
ticles [133], niosomes [134], microemulsion, microspheres,
and prodrug derivatization [135] .T h er e a d e ri sr e f e r r e dt o
the cited references for a comprehensive coverage on the
topic of ophthalmic drug delivery and the highlighted tech-
niques currently available.
The optimal drug delivery approach depends, to a sub-
stantial extent, on the physiochemical and pharmacokinetic
properties of the pharmacological agent to be administered.
Some of the highlighted techniques, although optimized for
ocular surface or anterior pole diseases, have resulted in
suﬃcient enhancement of drug penetration that they also
have utility for pharmacological treatment of ocular diseases
of the posterior segment. Several of the anti-inﬂammatoryJournal of Ophthalmology 13
and anti-VEGF pharmacological agents that are proposed in
this review to be used in combination with mTOR inhibitors
have been administered to the ocular surface using one of
the described drug delivery or formulation technologies to
treat retinal diseases. For instance, nanocomposites have
been used to deliver Diclofenac [136], and topical adminis-
tration of Nepafenac has been shown to reduce the extent of
microangiopathy in animal models of diabetic retinopathy
[118] and oxygen-induced retinopathy [137]. Nanoparticle
technology has been employed to enhance the surface pen-
etration of hydrophobic compounds such as glucocorticoids
to posterior ocular structures [138]. Furthermore, nanopar-
ticles injected into the vitreous have demonstrated intrareti-
nal localization for several months after initial dosing, there-
by, serving as a localized drug release depot [139].
A microparticle formulation containing an antagonist to
aleukocyteantigenappliedtopicallytotheocularsurfacehas
demonstrated suﬃcient ocular penetration to inﬂuence leu-
kocyte dynamics and vascular leakage in the retina, both
manifestationsofdiabeticretinopathy[140].Useofelectrical
currents applied to the ocular surface in the technique of
iontophoresis or macroesis are being used experimentally to
successfully obtain retinal concentrations of triamcinalone
and ranibizumab when applied on the sclera [141].
Additional techniques and methods have been optimized
with the speciﬁc aim of treating diseases of the posterior pole
[142–145]. These approaches permit a sustained and stable
multifold increase in drug concentration to reach the retina
without inducing systemic side eﬀects while improving ther-
apeutic outcome. Sustained-drug release intraocular im-
plants for delivery of triamcinalone [146] and polylactic-
glycolic acid microspheres to deliver dexamethasone [147]t o
treat diabetic retinal complications and inﬂammation have
been used successfully [148]. Lipid nanoparticles have been
used to deliver bevacizumab directly into the vitreous of
rabbits with the result of chronically increasing the concen-
tration and bioavailability of the drug in the vitreous several
folds [149].
These biodegradable or nonbiodegradable intraocular
implants can be placed in the vitreous or via cannulation in
the suprachoroidal space [150] to lower the frequency of
intraocular injections, improve drug bioavailability in the
retina, and circumvent the potential for systemic side eﬀects.
Of particular interest, in light of the theme of this review,
is the use of microemulsion to enhance the corneal per-
meation of the mTOR inhibitor everolimus with sustained
stability of the drug [151] and the use of thermoresponsive
hydrogels that have been used to deliver bevacizumab and
ranibizumab [152].
While it is unlikely that a single drug will be eﬃcacious
for managing all the various stages of diabetic retinopathy,
combinationorsequentialtherapeuticagentsaremoreaptto
yield beneﬁcial results. Combinatorial use of a dual mTOR
inhibitor with anti-VEGF antibodies or VEGF-trap could
neutralize cross-talk inducers of VEGF expression and be a
powerful combination approach to ocular anti-angiogenic
therapy. Compelling evidence for enhanced eﬃcacy of com-
bined drug therapy to combat ocular angiogenesis has been
previously presented, and the evidence underscores the
extensive overlap of regulatory signaling involved in the an-
giogenic cascade [153]. Potent synergistic eﬀects of combin-
ing angiostatic molecules aimed at divergent aspects of the
angiogenic process have resulted in more extensive suppres-
sion of the vasculature without adverse eﬀects on established
quiescent vasculature [154].
The combination of mTOR inhibitors with anti-inﬂam-
matory agents also provides a rational-based approach to
combatocularangiogenesisandearlyhemodynamic changes
in the retina. The mTOR inhibitors are uniquely suited to
address both early and advanced manifestations of diabetic
retinopathy.ThemTORinhibitorshavethepotentialtodelay
or prevent the progression of retinal microangiopathies
by helping to avert breakdown of blood-retinal barrier
by modulating HIF-α-mediated downstream activation of
growth factors. As the disease progresses and the charac-
teristic lesions are proliferative in nature, the inhibition of
PI3K/Akt/mTOR pathway would provide an eﬀective means
to abrogate neovascularization by shutting down prosurvival
growth factors, modulating the inﬂammatory cascade, pre-
venting angiogenesis, and promoting apoptosis of nascent
vessels.
Aswecontinuetounravelthecomplexityoftheinitiating
factors that contribute to the microangiopathy observed in
progressive diabetic retinopathy and gain further under-
standingofthenaturalprogressionofthediseaseitisimpera-
tive that emerging therapeutics like mTOR inhibitors be well
contemplated in the context of their mechanism of action,
stage progression of the retinopathy, and the critical timing
of pharmacological intervention. A drug can be ineﬀective
or even result in adverse eﬀects if implemented during an
inappropriate stage of disease progression. Therefore, man-
aging of the complex vasculopathy in diabetic retinopathy
will require elucidating the proper timing of when to admin-
ister the therapeutic agent for optimal eﬃcacy. Regardless
of the enigmatic components that remain with regards to
theelucidationofthemolecularpathwaysoperantindiabetic
retinopathy, these novel classes of therapeutics are likely
to produce better patient outcome for managing the wide-
spread and devastating disease of diabetic retinopathy. The
mTOR inhibitors, particularly when combined with other
pharmacologicalagentswouldappeartobeapromisingther-
apeutic modality.
The second-generation mTOR inhibitors discussed in
this review are well positioned to fulﬁll several key criteria
for being an optimal therapeutic for treatment of ocular
angiogenesis: (1) targets neovascularization by speciﬁc
mechanism, (2) delays or prevents the angiogenic phase of
the disease, (3) demonstrate speciﬁcity and selectivity for
aberrant vessels, (4) has a formulation for long-term delivery
with no apparent toxicity associated with chronic admin-
istration, (5) stabilize, or prevent further deterioration of
vision,(6)preventordelayinglate-stagecomplicationsofthe
disease such as detachment and scarring.
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